Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. This article provides an overview of the distinctive genetic mechanisms underlying FSHD, its clinical manifestations, including pedia...
Uloženo v:
| Vydáno v: | Continuum (Minneapolis, Minn.) Ročník 31; číslo 5; s. 1329 |
|---|---|
| Hlavní autor: | |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.10.2025
|
| Témata: | |
| ISSN: | 1538-6899, 1538-6899 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. This article provides an overview of the distinctive genetic mechanisms underlying FSHD, its clinical manifestations, including pediatric-specific features, treatment, and the evolving landscape of clinical trials targeting disease-modifying therapies.
FSHD arises from derepression of the transcription factor DUX4, which is toxic to skeletal muscle. This misexpression leads to a characteristic and progressive pattern of muscle weakness involving the facial, shoulder girdle, upper extremity, trunk, and leg muscles. Extramuscular manifestations, such as pain and fatigue, are frequently reported. Children with a severe, early-onset phenotype experience higher rates of extramuscular features, including hearing loss, cognitive impairment, and spinal deformities. Advances in the understanding of
as the causative gene, combined with innovations in gene therapy, gene editing, small-molecule development, and drug delivery, have catalyzed the initiation of several clinical trials focusing on disease-targeted treatments in the near future.
FSHD is caused by toxic expression of
and presents with progressive, often asymmetric muscle weakness and extramuscular manifestations in a subset of patients. Advances in genetic understanding and therapeutic development have led to clinical trials targeting
. Although care remains supportive, the field is entering an era of promising disease-modifying strategies. |
|---|---|
| AbstractList | Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. This article provides an overview of the distinctive genetic mechanisms underlying FSHD, its clinical manifestations, including pediatric-specific features, treatment, and the evolving landscape of clinical trials targeting disease-modifying therapies.
FSHD arises from derepression of the transcription factor DUX4, which is toxic to skeletal muscle. This misexpression leads to a characteristic and progressive pattern of muscle weakness involving the facial, shoulder girdle, upper extremity, trunk, and leg muscles. Extramuscular manifestations, such as pain and fatigue, are frequently reported. Children with a severe, early-onset phenotype experience higher rates of extramuscular features, including hearing loss, cognitive impairment, and spinal deformities. Advances in the understanding of
as the causative gene, combined with innovations in gene therapy, gene editing, small-molecule development, and drug delivery, have catalyzed the initiation of several clinical trials focusing on disease-targeted treatments in the near future.
FSHD is caused by toxic expression of
and presents with progressive, often asymmetric muscle weakness and extramuscular manifestations in a subset of patients. Advances in genetic understanding and therapeutic development have led to clinical trials targeting
. Although care remains supportive, the field is entering an era of promising disease-modifying strategies. Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. This article provides an overview of the distinctive genetic mechanisms underlying FSHD, its clinical manifestations, including pediatric-specific features, treatment, and the evolving landscape of clinical trials targeting disease-modifying therapies.OBJECTIVEFacioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. This article provides an overview of the distinctive genetic mechanisms underlying FSHD, its clinical manifestations, including pediatric-specific features, treatment, and the evolving landscape of clinical trials targeting disease-modifying therapies.FSHD arises from derepression of the transcription factor DUX4, which is toxic to skeletal muscle. This misexpression leads to a characteristic and progressive pattern of muscle weakness involving the facial, shoulder girdle, upper extremity, trunk, and leg muscles. Extramuscular manifestations, such as pain and fatigue, are frequently reported. Children with a severe, early-onset phenotype experience higher rates of extramuscular features, including hearing loss, cognitive impairment, and spinal deformities. Advances in the understanding of DUX4 as the causative gene, combined with innovations in gene therapy, gene editing, small-molecule development, and drug delivery, have catalyzed the initiation of several clinical trials focusing on disease-targeted treatments in the near future.LATEST DEVELOPMENTSFSHD arises from derepression of the transcription factor DUX4, which is toxic to skeletal muscle. This misexpression leads to a characteristic and progressive pattern of muscle weakness involving the facial, shoulder girdle, upper extremity, trunk, and leg muscles. Extramuscular manifestations, such as pain and fatigue, are frequently reported. Children with a severe, early-onset phenotype experience higher rates of extramuscular features, including hearing loss, cognitive impairment, and spinal deformities. Advances in the understanding of DUX4 as the causative gene, combined with innovations in gene therapy, gene editing, small-molecule development, and drug delivery, have catalyzed the initiation of several clinical trials focusing on disease-targeted treatments in the near future.FSHD is caused by toxic expression of DUX4 and presents with progressive, often asymmetric muscle weakness and extramuscular manifestations in a subset of patients. Advances in genetic understanding and therapeutic development have led to clinical trials targeting DUX4. Although care remains supportive, the field is entering an era of promising disease-modifying strategies.ESSENTIAL POINTSFSHD is caused by toxic expression of DUX4 and presents with progressive, often asymmetric muscle weakness and extramuscular manifestations in a subset of patients. Advances in genetic understanding and therapeutic development have led to clinical trials targeting DUX4. Although care remains supportive, the field is entering an era of promising disease-modifying strategies. |
| Author | Knox, Renatta N |
| Author_xml | – sequence: 1 givenname: Renatta N surname: Knox fullname: Knox, Renatta N |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41037169$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNjztPwzAYRS1URB_wE0CdEEuK37FHVCggFbF0jxznsxrkxMGOh_x7hChS73LucHSlu0SzPvSA0C3BG0IJfbShHzf4LEQSfoEWRDBVSKX17KzP0TKlL4wZLZm8QnNOMCuJ1At0vzO2DcmaIftwzB1E49cfOdnsTVw_T2mMYThO1-jSGZ_g5sQVOuxeDtu3Yv_5-r592heWUs4LoRgQ7GRNDGdWUU6ZFa5sasGNhlqVQhLXOK4pbkBgKRrjagVSY-BgCF2hh7_ZIYbvDGmsujZZ8N70EHKqGBWSaYH5r3p3UnPdQVMNse1MnKr_a_QHO8lS3w |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1212/cont.0000000000001614 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1538-6899 |
| ExternalDocumentID | 41037169 |
| Genre | Journal Article Review Case Reports |
| GroupedDBID | --- .Z2 0R~ 53G 5VS AAAAV AAHPQ AAIQE AAJCS AARTV AASCR ABASU ABBUW ABDIG ABIVO ABJNI ABPXF ABVCZ ABXVJ ABXYN ABZZY ACBKD ACDDN ACEWG ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADGGA ADHPY ADKSD AEBDS AFBFQ AFDTB AFEXH AFNMH AHQNM AHQVU AHVBC AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK C45 CGR CUY CVF DIWNM E.X EBS ECM EEVPB EIF EJD EX3 FCALG FL- GNXGY GQDEL HLJTE HYE HZ~ IKREB IN~ KD2 L-C NPM O9- ODMTH OHYEH OPUJH OVD OVDNE OXXIT RLZ S4S TEORI TSPGW V2I W3M WOQ WOW 7X8 |
| ID | FETCH-LOGICAL-c2244-583e10f6b1a43c82423c5f7db54a9eb87561fdf4920de5065dafb8e690e4ea12 |
| IEDL.DBID | 7X8 |
| ISSN | 1538-6899 |
| IngestDate | Thu Oct 02 19:14:06 EDT 2025 Sun Nov 16 02:01:21 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2244-583e10f6b1a43c82423c5f7db54a9eb87561fdf4920de5065dafb8e690e4ea12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Review-3 content type line 23 ObjectType-Case Study-5 ObjectType-Feature-2 ObjectType-Report-4 |
| PMID | 41037169 |
| PQID | 3256395041 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3256395041 pubmed_primary_41037169 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Oct 20251001 |
| PublicationDateYYYYMMDD | 2025-10-01 |
| PublicationDate_xml | – month: 10 year: 2025 text: 2025-Oct |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Continuum (Minneapolis, Minn.) |
| PublicationTitleAlternate | Continuum (Minneap Minn) |
| PublicationYear | 2025 |
| SSID | ssj0032736 |
| Score | 2.3511207 |
| SecondaryResourceType | review_article |
| Snippet | Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1329 |
| SubjectTerms | Homeodomain Proteins - genetics Humans Male Muscular Dystrophy, Facioscapulohumeral - diagnosis Muscular Dystrophy, Facioscapulohumeral - genetics Muscular Dystrophy, Facioscapulohumeral - physiopathology Muscular Dystrophy, Facioscapulohumeral - therapy Young Adult |
| Title | Facioscapulohumeral Muscular Dystrophy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41037169 https://www.proquest.com/docview/3256395041 |
| Volume | 31 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UevDiglvdiCDehiaZySRzElGLl5YeeugtzPIGC5K0TSP4732TpHoSBOeQ20Bme-9760fIneE2NsJwquNUUm6MpTpjivI0USkiBOsy3ZBNpONxNpvJSedwq7q0yo1MbAS1LY33kQ8Y6mYmk5BHD4sl9axRPrraUWhskx5DKONTutLZdxSBoWoWbb_UjAo0LLoKHpTWA58I3vYu7AYiH_47ymy0zfDgv_95SPY7nBk8thfjiGxBcUzuh8rMy8qoRf1evtWNPyoY1W0uavD8Wa1XJW77CZkOX6ZPr7QjSqAGNTD3lVMQhU7oSHFmMg-RTOJSqxOuJGg0SUTkrOMyDi0kCDqscjoDNIyBg4riU7JTlAWck0CERjLm2efBcYMHJUAYBs5FUgMPoU9uN6vO8R764IIqoKyr_GfdfXLWbl2-aBtm5NwXI0ZCXvxh9iXZiz3FbpMvd0V6Dl8hXJNd87GeV6ub5oDxO56MvgBI8a9m |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Facioscapulohumeral+Muscular+Dystrophy&rft.jtitle=Continuum+%28Minneapolis%2C+Minn.%29&rft.au=Knox%2C+Renatta+N&rft.date=2025-10-01&rft.eissn=1538-6899&rft.volume=31&rft.issue=5&rft.spage=1329&rft_id=info:doi/10.1212%2Fcont.0000000000001614&rft_id=info%3Apmid%2F41037169&rft_id=info%3Apmid%2F41037169&rft.externalDocID=41037169 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-6899&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-6899&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-6899&client=summon |